🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rachel M. Layman

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0002-8663-0331
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy”.

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Investigational New Drugs(2023)10.1007/s10637-023-01357-4
N/A
0.285DataRank · unranked
5 citations

Ryan Sun, Roland L. Bassett, Lei Huo, Jeffrey T. Chang, Mediget Teshome +24 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011
N/A
0DataRank · unranked
45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

npj Breast Cancer(2022)10.1038/s41523-022-00499-7
N/A
0DataRank · unranked
19 citations

Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Hassan, Debu Tripathy, Rachel M. Layman +1 more

Inclusion of premenopausal women in breast cancer clinical trials

The Breast(2022)10.1016/j.breast.2022.10.013
N/A
0DataRank · unranked
4 citations

Ramez Kouzy, Joseph Abi Jaoude, Roshal R. Patel, Rachel M. Layman, Sharon H. Giordano +5 more

Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma

European Journal of Cancer(2023)10.1016/j.ejca.2023.113250
N/A
0DataRank · unranked
5 citations

Akshara Singareeka Raghavendra, Roland L. Bassett, Matthias Christgen, Lavinia P. Middleton, Mediget Teshome +6 more

Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma

The Oncologist(2023)10.1093/oncolo/oyad317
N/A
0DataRank · unranked
3 citations

Wei Qaio, Yu Shen, Akshara Singareeka Raghavendra, Debasish Tripathy, Rachel M. Layman +1 more

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07551-z
N/A
0DataRank · unranked
12 citations

H. Boutrid, Mahmoud Kassem, Mahmoud Abdel‐Rasoul, Cynthia Timmers, Maryam B. Lustberg +19 more

Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities

Annals of Surgical Oncology(2024)10.1245/s10434-024-15713-y
N/A
0DataRank · unranked
5 citations

Kerollos Nashat Wanis, Sydnee Brown, Anthony Lucci, Susie X. Sun, Taiwo Adesoye +6 more

Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0593
N/A
0DataRank · unranked
2 citations

Moises Tacam, Alex W. Tan, Mary Kathryn Pitner, LaKesla R. Iles, Xiaoding Hu +16 more

Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07795-3
N/A
0DataRank · unranked
0 citations

N Sridhar, Megumi Kai, Wenli Dong, Shen Yu, Savitri Krishnamurthy +14 more

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

The Oncologist(2020)10.1634/theoncologist.2020-0039
N/A
0DataRank · unranked
14 citations

Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrózek +23 more

Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer

Cancer Epidemiology Biomarkers & Prevention(2025)10.1158/1055-9965.epi-25-0829
N/A
0DataRank · unranked
0 citations

Rebecca S. Tidwell, Megumi Kai, Anthony Lucci, Wendy A. Woodward, Helen M. Johnson +20 more